Immune responses of cattle vaccinated by various routes with Mycobacterium bovis Bacillus Calmette-Guérin (BCG)

被引:0
|
作者
Palmer, Mitchell V. [1 ]
Hwang, Soyoun [2 ]
Kanipe, Carly [1 ,3 ]
Putz, Ellie J. [1 ]
Fernandes, Luis Guilherme Virgilio [4 ]
Didkowska, Anna [5 ]
Boggiatto, Paola M. [1 ]
机构
[1] Natl Anim Dis Ctr, Agr Res Serv, Bacterial Dis Livestock Res Unit, 1920 Dayton Ave, Ames, IA 50010 USA
[2] USDA, Ctr Vet Biol Anim & Plant Hlth Inspection Serv, 1920 Dayton Ave, Ames, IA 50010 USA
[3] Iowa State Univ, Coll Vet Med, Immunobiol Grad Program, 1800 Christensen Dr, Ames, IA 50010 USA
[4] Oak Ridge Inst Sci & Educ, 1299 Bethel Valley Rd, Oak Ridge, TN 37830 USA
[5] Warsaw Univ Life Sci SGGW, Inst Vet Med, Dept Food Hyg & Publ Hlth Protect, Nowoursynowska 159, PL-02776 Warsaw, Poland
关键词
BCG; Bovine; Lyophilization; Mycobacteria; Oral; Tuberculosis; Vaccination; CALMETTE-GUERIN VACCINATION; FORMULATION INDUCES RESISTANCE; T-CELL RESPONSES; ORAL VACCINATION; PULMONARY TUBERCULOSIS; PROTECTION; RABIES; ELIMINATION; COMBINATION; EFFICACY;
D O I
10.1186/s12917-024-04452-7
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
BackgroundMycobacterium bovis BCG is the human tuberculosis vaccine and is the oldest vaccine still in use today with over 4 billion people vaccinated since 1921. The BCG vaccine has also been investigated experimentally in cattle and wildlife by various routes including oral and parenteral. Thus far, oral vaccination studies of cattle have involved liquid BCG or liquid BCG incorporated into a lipid matrix. Lyophilization is an established technique used for stabilizing bioproducts such as vaccines.MethodsIn the current study, cattle were vaccinated in two phases. In each phase, cattle were divided into three groups. Group 1 received BCG injected SQ, Group 2 received liquid BCG delivered to the posterior oral cavity, Group 3 orally consumed lyophilized BCG contained within a gelatin capsule placed within a small amount of a commercial alfalfa product.ResultsNo vaccinated cattle were positive by an interferon gamma release assay. All but 4 animals were negative by tuberculin skin testing prior to vaccination: the 4 non-negative animals being categorized as suspects. Sixteen weeks post-vaccination all but 1 animal was negative, it being categorized as a suspect. An in vitro antigen stimulation assay and flow cytometry were used to detect antigen-specific CD4, CD8 and gamma delta T cell responses following vaccination. Oral vaccination of animals with lyophilized BCG did not result in any increases in the frequency of CD4, CD8 or gamma delta T cell proliferative or IFN-gamma responses at any of the time points analyzed in either phase 1 or 2. In contrast, vaccination with BCG SQ and liquid BCG delivered to the posterior pharynx, resulted in an increase in the frequency of proliferating and IFN-gamma-producing CD4 T cells with peak responses at 9-12 weeks post-vaccination. Similar to oral lyophilized BCG vaccinated animals, we did not observe any significant increases in the frequency of CD8 and gamma delta T cell proliferative and IFN-gamma responses following SQ or oral liquid vaccinated animals.ConclusionsThese data would suggest that vaccination with oral lyophilized BCG does not induce a measurable, antigen-specific cell mediated responses in the periphery, when compared to BCG administered SQ or liquid BCG administered via the oral route. However, vaccination with either SQ or liquid BCG delivered to the posterior pharynx does induce measurable CD4 T cell responses in the periphery.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Revitalizing Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer: Nanotechnology and Bioengineering Approaches
    Lv, Maoxin
    Shang, Shihao
    Liu, Kepu
    Wang, Yuliang
    Xu, Peng
    Song, Hao
    Zhang, Jie
    Sun, Zelong
    Yan, Yuhao
    Zhu, Zheng
    Wu, Hao
    Li, Hao
    PHARMACEUTICS, 2024, 16 (08)
  • [22] Immune responses of elk to Mycobacterium bovis bacillus Calmette Guerin vaccination
    Waters, WR
    Palmer, MV
    Olsen, SC
    Sacco, RE
    Whipple, DL
    VACCINE, 2003, 21 (13-14) : 1518 - 1526
  • [23] CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer
    Steinberg, Gary D.
    Shore, Neal D.
    Redorta, Joan Palou
    Galsky, Matthew D.
    Bedke, Jens
    Ku, Ja Hyeon
    Kretkowski, Michal
    Hu, Hailong
    Penkov, Konstantin
    Vermette, Jennifer J.
    Tarazi, Jamal C.
    Randall, Alison E.
    Pierce, Kristen J.
    Saltzstein, Daniel
    Powles, Thomas B.
    FUTURE ONCOLOGY, 2024, 20 (14) : 891 - 901
  • [24] Could Hyaluronic acid (HA) reduce Bacillus Calmette-Guérin (BCG) local side effects? Results of a pilot study
    Luca Topazio
    Roberto Miano
    Valentina Maurelli
    Gabriele Gaziev
    Mauro Gacci
    Valerio Iacovelli
    Enrico Finazzi-Agrò
    BMC Urology, 14
  • [25] Complex genetic control of susceptibility to Mycobacterium bovis (Bacille Calmette-Guérin) infection in wild-derived Mus spretus mice
    K Turcotte
    J C Loredo-Osti
    P Fortin
    E Schurr
    K Morgan
    P Gros
    Genes & Immunity, 2006, 7 : 684 - 687
  • [26] Tuberculin skin test in bacille Calmette-Gu,rin-vaccinated children: how should we interpret the results?
    Pineiro, Roi
    Jose Mellado, Maria
    Jose Cilleruelo, Maria
    Garcia-Ascaso, Marta
    Medina-Claros, Antonio
    Garcia-Hortelano, Milagros
    EUROPEAN JOURNAL OF PEDIATRICS, 2012, 171 (11) : 1625 - 1632
  • [27] Antibacterial activities of gold and silver nanoparticles against Escherichia coli and bacillus Calmette-Guérin
    Yan Zhou
    Ying Kong
    Subrata Kundu
    Jeffrey D Cirillo
    Hong Liang
    Journal of Nanobiotechnology, 10
  • [28] Isolated Strains of Nontuberculous Mycobacterium Interfere with Immune Responses Associated with Mycobacterium bovis BCG Vaccination
    Wang, Chunfang
    Qi, Huarui
    Jiang, Xiuyun
    Ma, Hongxia
    Qian, Aidong
    Wang, Chunfeng
    BIOTECHNOLOGY, CHEMICAL AND MATERIALS ENGINEERING III, PTS 1 AND 2, 2014, 884-885 : 450 - +
  • [29] Vaccination of cattle with Mycobacterium bovis BCG by a combination of systemic and oral routes
    Buddle, Bryce M.
    Denis, Michel
    Aldwell, Frank E.
    Vordermeier, H. Martin
    Hewinson, R. Glyn
    Wedlock, D. Neil
    TUBERCULOSIS, 2008, 88 (06) : 595 - 600
  • [30] Intravesical gemcitabine for treatment of superficial bladder cancer not responding to Bacillus Calmette-Guérin vaccine
    Mohamed Ali Elkoushy
    African Journal of Urology, 2010, 16 (4) : 110 - 116